---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-26-000038"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2026-06-09T20:02:51+00:00"
generated_at: "2026-06-09T20:04:57.366304+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Ligand shareholders elect directors, approve equity plan amendment at annual meeting

## Summary
- All eight director nominees elected; Martine Zimmermann received 17,319,859 votes for, highest of the slate.
- Ernst & Young ratified as independent auditor for FY2026 with 18,526,515 votes for, 257,924 against.
- Non-binding say-on-pay resolution approved: 16,497,712 for, 1,021,948 against, 14,099 abstentions.
- Amendment and restatement of 2002 Stock Incentive Plan approved: 16,643,281 for, 870,556 against.
- All votes had substantial majority support; no director received less than 16.2M votes for.

## SEC filing metadata
- accession: 0000886163-26-000038
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2026-06-09T20:02:51+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/0000886163-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/lgnd-20260605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-26-000038
- JSON: https://secwatch.observer/filing/0000886163-26-000038.json
- Plain text: https://secwatch.observer/filing/0000886163-26-000038.txt

## Key facts
- Shareholder Votes
  LIGAND PHARMACEUTICALS INC shareholders approved Approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers.
  - Proposal: say on pay
  - Outcome: passed
  source text: Proposal 3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers. In accordance with the results below, the proposal was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/0000886163-26-000038-index.htm
- Shareholder Votes
  LIGAND PHARMACEUTICALS INC shareholders approved Approval of an amendment and restatement of the Company's 2002 Stock Incentive Plan.
  - Proposal: equity plan
  - Outcome: passed
  source text: Proposal 4. The approval of an amendment and restatement of the Company's 2002 Stock Incentive Plan. In accordance with the results below, the proposal was approved.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/0000886163-26-000038-index.htm
- Shareholder Votes
  LIGAND PHARMACEUTICALS INC shareholders approved Election of eight members of the Board of Directors for terms expiring at the 2027 annual meeting.
  - Proposal: director election
  - Outcome: passed
  source text: Proposal 1. The election of eight members of the Board of Directors of the Company for terms expiring at the 2027 annual meeting of stockholders. In accordance with the results below, each nominee was elected to serve as a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/0000886163-26-000038-index.htm
- Shareholder Votes
  LIGAND PHARMACEUTICALS INC shareholders approved Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-12-31
  source text: Proposal 2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. In accordance with the results below, the selection of Ernst & Young LLP was ratified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616326000038/0000886163-26-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.